FDA Approves New Therapy for Metastatic Breast Cancer

3

 

new breast cancer treatment approved

Harold J. Burstein, MD, PhD

The U.S. Food and Drug Administration has approved a new treatment  for women with advanced (metastatic) breast cancer. The new therapy, palbociclib, will be used to treat postmenopausal women with metastatic estrogen receptor-positive (ER-positive) breast cancer who have not received previous treatment.

Palbociclib, which is marketed under the name Ibrance, will be used in combination with another breast cancer drug, letrozole.

“This is a new class of drugs that has been effective in treating this particular pathway in cancer, and it has improved outcomes for patients with advanced ER-positive breast cancer, one of the most common forms of the disease,” says Harold J. Burstein, MD, PhD, a breast cancer specialist with the Susan F. Smith Center for Women’s Cancers at Dana-Farber.

Palbociclib was tested in a trial of 165 women with ER-positive advanced breast cancer who had not received previous treatment. Patients who were treated with palbociclib and letrozole lived about 20 months without the disease progressing. Women who received just the letrozole lived about 10 months without the disease progressing.

New drug approved for metastatic breast cancer

Sara Tolaney, MD, and Geoffrey Shapiro, MD, help connect breast cancer patients with clinical trials.

The drug’s effectiveness is also being tested in treating early stage breast cancer, Burstein says.

The FDA approved palbociclib under its accelerated approval program, which allows faster approval of a drug if it is used to treat a serious or life-threatening disease and clinical trial data shows it is likely to benefit patients. The approval was based on a small, randomized phase II study and full approval will depend on results of a phase III trial that has not yet reported data.

Comments Sort By Newest

3 thoughts on “FDA Approves New Therapy for Metastatic Breast Cancer

  1. Dear Kathryn —
    Thank you for your question and for reading our Insight blog. We spoke with Dr. Burstein, who told us there are several ongoing studies looking at this class of drug in women who have already had treatment for ER+ breast cancer. I hope this is helpful. Wishing you all the best!

  2. Are there plans or a timeline for approval for stage 4 women who have already had treatment? There are so many of us who have been on hormonal therapy already for our metastases, and so many of us who have developed metastases after treatment for ER+ early stage cancer where the standard of care is tamixifen or an AI. Is this breakthrough out of reach for every one of us?

  3. Are there plans or a timeline for approval for stage 4 women who have already had treatment? There are so many of us who have been on hormonal therapy already for our metastases, and so many of us who have developed metastases after treatment for ER+ early stage cancer where the standard of care is tamixifen or an AI. Is this breakthrough out of reach for every one of us?

  4. Dear Kathryn —
    Thank you for your question and for reading our Insight blog. We spoke with Dr. Burstein, who told us there are several ongoing studies looking at this class of drug in women who have already had treatment for ER+ breast cancer. I hope this is helpful. Wishing you all the best!

Comments are closed.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dana-Farber #researchers have shown that clonal hematopoiesis of indeterminate potential (CHIP) - the presence of s… https://t.co/ZlmXSeyKfZ
Dana-Farber @danafarber
CRISPR, a powerful new tool for editing the #DNA instruction manual in animals and humans, is proving a boon to… https://t.co/pCzS3riHPS

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.